Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 18/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 8/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.72 |
| ▸ | SYK | P43405 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14658544 | 1.00 | MAPK8 (1.00) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL22447049 | 1.00 | MAPK8 (1.00) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL14659020 | 0.98 | MAPK8 (0.96) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL14657983 | 0.91 | MAPK8 (0.84) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL14658027 | 0.91 | MAPK8 (0.84) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL23244452 | 0.91 | MAPK8 (0.84) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL14658200 | 0.91 | MAPK8 (0.84) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL14658381 | 0.91 | MAPK8 (0.84) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL24591432 | 0.90 | MAPK8 (0.82) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL14658827 | 0.90 | MAPK8 (0.81) | MAPK8MAPK9ADORA3MAPK10SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097940-A1 | THERAPY FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-3712134-B1 | SALTS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE | SIGNAL PHARM LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-2699553-B1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3233809-B1 | FORMULATIONS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE | SIGNAL PHARM LLC (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3795553-A1 | METHODS OF SYNTHESIS OF (1R,2R,5R)-5-AMINO-2-METHYLCYCLOHEXANOL HYDROCHLORIDE AND INTERMEDIATES USEFUL THEREIN | Celgene Corporation (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3738954-A1 | METHOD OF PREPARATION OF SUBSTITUTED 2,4-DIAMINO-PYRIMIDINE-5-CARBOXAMIDES | Signal Pharmaceuticals, LLC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3712134-A1 | SALTS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE | Signal Pharmaceuticals, LLC (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3099302-B1 | CRYSTALLINE FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE | SIGNAL PHARM LLC (US) | 2020-06-17 | — | — | EP | disclosed |